Ocular Therapeutix (OCUL) PT Lowered to $20 at Scotiabank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts OCUL Hot Sheet
Price: $7.14 +4.69%
Rating Summary:
21 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
21 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Scotiabank analyst Greg Harrison lowered the price target on Ocular Therapeutix (NASDAQ: OCUL) to $20.00 (from $22.00) while maintaining a Sector Outperform rating.
You May Also Be Interested In
- Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026
- Matador (MTDR) PT Raised to $66 at Truist Securities
- Pfizer (PFE) PT Raised to $40 at Argus
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
